A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19. (VICTORIA)

First published 19/01/2022

Last updated 23/04/2024

EU PAS number:

EUPAS44425

Study

Finalised

Documents

Study protocol

Initial protocol

EUPAS44425 D8111C00010 - Protocol_18Mar2022_Redacted

English (3.01 MB - PDF) View document

Updated protocol

D8111C00010-CSP Amendment-3-v4_Redacted_PDFA

First published: 22/02/2024

English (1.43 MB - PDF) View document

Study results

D8111C00010-CSR synopsis_Redacted_PDFA

English (1.48 MB - PDF) View document

Study report

Other information

Secondary tabs